New research shows that melanoma cells not only develop resistance to MAPK (Mitogen-Activated Protein Kinase) inhibitors commonly used to treat it, but also actively suppress the immune cells that would otherwise help eliminate melanoma. The study, published in Nature Communications, identified two cell proteins, ABL1 and ABL2, as key drivers of both processes. These proteins help control cell functions such as growth, survival, and communication with other cells, and when th